Montelukast Zentiva is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. In clinical studies, Montelukast Zentiva inhibits bronchoconstriction due to inhaled LTD4 at doses as low as 5 mg. Bronchodilation was observed within 2 hours of oral...